Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein
- PMID: 19935868
- DOI: 10.1139/o09-044
Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein
Abstract
Signal transducer and activator of transcription protein 3 (STAT3) is a latent cytosolic transcription factor that is widely recognized as being a master regulator of the cellular functions that lead to the cancer phenotype. Constitutively activated STAT3 protein activity is routinely observed in human cancers, promoting uncontrolled cell proliferation and suppressing apoptosis. Until relatively recently, inhibition of STAT3 transcriptional activity was achieved indirectly via suppression of upstream kinase activators and extracellular cytokine and (or) growth factor stimuli. However, activated STAT3 forms transcriptionally functional STAT3-STAT3 dimers, providing a valid juncture for targeted downstream molecular inhibition. STAT3's prominent role in cancer has seen a decade of innovative and novel approaches to targeting constitutively active STAT3 protein-protein complexes. This mini-review outlines the progress made towards identifying molecular agents capable of silencing aberrant STAT3 signalling through the disruption of STAT3 complexation events.
Similar articles
-
Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report.Anticancer Drugs. 2011 Feb;22(2):115-27. doi: 10.1097/CAD.0b013e328341185b. Anticancer Drugs. 2011. PMID: 21063201 Review.
-
The intracellular delivery of a recombinant peptide derived from the acidic domain of PIAS3 inhibits STAT3 transactivation and induces tumor cell death.Mol Cancer Res. 2010 Apr;8(4):539-53. doi: 10.1158/1541-7786.MCR-09-0417. Epub 2010 Apr 6. Mol Cancer Res. 2010. PMID: 20371673
-
Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signaling.Nat Med. 2005 Aug;11(8):845-52. doi: 10.1038/nm1282. Epub 2005 Jul 24. Nat Med. 2005. PMID: 16041381
-
Determinants governing the potency of STAT3 activation via the individual STAT3-recruiting motifs of gp130.Cell Signal. 2006 Jan;18(1):40-9. doi: 10.1016/j.cellsig.2005.03.019. Epub 2005 May 31. Cell Signal. 2006. PMID: 15927449
-
Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution.Ann N Y Acad Sci. 2006 Dec;1091:151-69. doi: 10.1196/annals.1378.063. Ann N Y Acad Sci. 2006. PMID: 17341611 Review.
Cited by
-
Evaluation of quantitative assays for the identification of direct signal transducer and activator of transcription 3 (STAT3) inhibitors.Oncotarget. 2016 Nov 22;7(47):77998-78008. doi: 10.18632/oncotarget.12868. Oncotarget. 2016. PMID: 27793003 Free PMC article.
-
Leptin signaling molecular actions and drug target in hepatocellular carcinoma.Drug Des Devel Ther. 2014 Nov 14;8:2295-302. doi: 10.2147/DDDT.S69004. eCollection 2014. Drug Des Devel Ther. 2014. PMID: 25484575 Free PMC article. Review.
-
Antagonism of the Stat3-Stat3 protein dimer with salicylic acid based small molecules.ChemMedChem. 2011 Aug 1;6(8):1459-70. doi: 10.1002/cmdc.201100194. Epub 2011 May 25. ChemMedChem. 2011. PMID: 21618433 Free PMC article.
-
Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas.Expert Opin Ther Targets. 2018 Jan;22(1):45-57. doi: 10.1080/14728222.2018.1406924. Epub 2017 Nov 24. Expert Opin Ther Targets. 2018. PMID: 29148847 Free PMC article. Review.
-
Comparative STAT3-Regulated Gene Expression Profile in Renal Cell Carcinoma Subtypes.Front Oncol. 2019 Feb 26;9:72. doi: 10.3389/fonc.2019.00072. eCollection 2019. Front Oncol. 2019. PMID: 30863721 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous